{
    "id": 1907,
    "name": "malignant fibrous histiocytoma",
    "source": "DOID",
    "definition": null,
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:1907",
    "evidence": [
        {
            "id": 9399,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EHop-016 inhibited AKT activation and increased apoptosis and reduced growth of a myxofibrosarcoma cell line in culture, and inhibited tumor growth in xenograft models (PMID: 27577794).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4100,
                "therapyName": "EHop-016",
                "synonyms": null
            },
            "indication": {
                "id": 1907,
                "name": "malignant fibrous histiocytoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7137,
                    "pubMedId": 27577794,
                    "title": "Integrin-\u03b110 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27577794"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9400,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of EHop-016 and IPA-3 resulted in increased apoptosis and reduced growth of a myxofibrosarcoma cell line in culture compared to either agent alone (PMID: 27577794).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5013,
                "therapyName": "EHop-016 + IPA-3",
                "synonyms": null
            },
            "indication": {
                "id": 1907,
                "name": "malignant fibrous histiocytoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7137,
                    "pubMedId": 27577794,
                    "title": "Integrin-\u03b110 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27577794"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9401,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of EHop-016 and Sapanisertib (MLN0128) resulted in increased apoptosis and reduced growth of a myxofibrosarcoma cell line in culture, and resulted in greater tumor growth inhibition in myxofibrosarcoma cell line xenograft models compared to either agent alone (PMID: 27577794).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5012,
                "therapyName": "EHop-016 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 1907,
                "name": "malignant fibrous histiocytoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7137,
                    "pubMedId": 27577794,
                    "title": "Integrin-\u03b110 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27577794"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9402,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, IPA-3 increased apoptosis and inhibited growth of a myxofibrosarcoma cell line in culture (PMID: 27577794).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3329,
                "therapyName": "IPA-3",
                "synonyms": null
            },
            "indication": {
                "id": 1907,
                "name": "malignant fibrous histiocytoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7137,
                    "pubMedId": 27577794,
                    "title": "Integrin-\u03b110 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27577794"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9403,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Sapanisertib (MLN0128) resulted in growth suppression and arrest in a myxofibrosarcoma cell line in culture, and inhibited tumor growth in myxofibrosarcoma cell line xenograft models (PMID: 27577794).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 1907,
                "name": "malignant fibrous histiocytoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7137,
                    "pubMedId": 27577794,
                    "title": "Integrin-\u03b110 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27577794"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT02584309",
            "title": "Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5153,
                    "therapyName": "Dexrazoxane",
                    "synonyms": null
                },
                {
                    "id": 4140,
                    "therapyName": "Doxorubicin + Olaratumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03092323",
            "title": "A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03190174",
            "title": "Nivolumab (Opdivo) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5931,
                    "therapyName": "Nab-Rapamycin + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03282344",
            "title": "A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5076,
                    "therapyName": "Nivolumab + NKTR-214",
                    "synonyms": null
                }
            ]
        }
    ]
}